Tempest Therapeutics Inc. Common Stock (TPST)

FairStock Score: 60/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Mr. Market is offering Tempest Therapeutics at $0.68 a share, a $10.1 million market value as of the 2026-10-13 close. This is not a business in the ordinary sense. It is a clinical-stage cancer drug developer with four employees and no reported revenue. The filed results show losses in each of the last four years: net income of -$29.5M in FY2023, -$41.8M in FY2024, -$26.3M in FY2025, and -$27.7M in fiscal Q1 2026 (quarter ended 2026-03-31). In fiscal Q2 2026 (quarter ended 2026-06-30), net income was -$5.2M and diluted EPS -$0.34. Trailing free cash flow was -$20.7M, a FairStock calculation, and FCF yield was -205.6%. The balance sheet looks stretched: debt-to-equity 1.22, ROE -931.14%, ROCE -79.37%, P/B 11.35, Piotroski 0/9, and Altman Z-score -39.79, all FairStock calculations. The P/E is negative at -0.19, so it says nothing about value. There is no durable moat I can identify; any edge rests on clinical data, patents, and regulatory outcomes I cannot underwrite from these figures. The stock ranged from $0.68 to $11.98 over the past 52 weeks, a reminder of how speculative biotech pricing can be. Growth is not visible in revenue; losses have varied but remain substantial. Graham would demand a margin of safety in assets or earnings, and Buffett would ask for durable competitive advantage. Here, the price may be low, but the business quality and financial health are fragile. It is a lottery-like clinical-stage venture, not a compounding franchise.

In plain English: Tempest Therapeutics is a tiny company testing experimental cancer drugs. It has no reported revenue and has lost money in each of the last four years. The stock price is very low, but the company's numbers are weak, so it does not look like a stable bargain; its value depends mostly on whether its drug trials succeed.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer